Generic name:rituximab-arrx (intravenous route) [ ri-TUX-i-mab-- arrx ]
Drug class:CD20 monoclonal antibodies
Medically reviewed by Drugs.com. Last updated on May 5, 2022.
Warning: Fatal Infusion-Related Reactions, Severe Mucocutaneous Reactions, Hepatitis B Virus Reactivation, and Progressive Multifocal LeukoencephalopathyFatal infusion-related reactions within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with first infusion. Monitor patients and discontinue rituximab-arrx infusion for severe reactions.Severe mucocutaneous reactions, some with fatal outcomes.Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death.Progressive multifocal leukoencephalopathy (PML) resulting in death .
Commonly used brand name(s)
In the U.S.
- Riabni
Available Dosage Forms:
- Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Rituximab
Uses for Riabni
Rituximab-arrx injection is used alone or together with other medicines (eg, cyclophosphamide, doxorubicin, vincristine, prednisone, or anthracycline medicine) to treat relapsed (cancer that has come back), refractory (cancer that did not respond to treatment), previously untreated, or non-progressing non-Hodgkin's lymphoma (NHL). It helps the immune system destroy cancer cells. Rituximab-arrx is a monoclonal antibody.
Rituximab-arrx injection is also used together with other medicines (eg, fludarabine and cyclophosphamide) to treat chronic lymphocytic leukemia (CLL).
Rituximab-arrx injection is used together with steroids to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). These are immune disorders that cause blood vessels to be inflamed.
This medicine is to be given only by or under the direct supervision of your doctor.
Before using Riabni
In deciding to use a medicine, the risks of taking the medicine must be weighe..
